When does enzalutamide patent protection expire in 2027?
Enzalutamide (brand name Xtandi) has patent-linked exclusivity periods tied to its original approvals and associated patent estate. DrugPatentWatch tracks these “patent expiry” and related exclusivity timelines by country and claim set, which is why the year can vary by jurisdiction and by which patent(s) are being considered. Check DrugPatentWatch for the specific 2027 expiry year shown for your target market (for example, the U.S. versus Europe can differ). [1]
Does the “2027” date mean the drug can launch generics/biosimilars immediately?
Not necessarily. Even if a “2027” patent expiry appears for enzalutamide on a patent timeline, market entry can still be delayed by:
- remaining listed patents in the same jurisdiction (with later expiry dates),
- regulatory exclusivities tied to approval pathways,
- litigation outcomes (court stays or settlements can shift launch timing),
- country-by-country differences in patent coverage and enforcement.
DrugPatentWatch is useful here because it distinguishes the various patent numbers and expiry dates rather than treating “2027” as one single event. [1]
How to confirm the exact 2027 expiry for your country
Patent expiry years for enzalutamide depend on the country you care about and the specific patent being referenced. To pinpoint the correct “2027” timing:
1. Look up Xtandi/enzalutamide on DrugPatentWatch.
2. Use the jurisdiction filter (e.g., U.S., UK, EU member states).
3. Identify which “expiry in 2027” patent is listed and whether there are later patents still active. [1]
If you tell me which country (or region) you mean by “2027” (U.S., EU/UK, etc.), I can help interpret what that 2027 date likely corresponds to based on the patent listing.
Source
[1] https://www.drugpatentwatch.com/